Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 14/20 | 0.51 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851539 | 0.94 | GPR52 (0.47) | GPR52LIPGNR4A2ALDH1A1KDM4E | |
| SCHEMBL1858465 | 0.85 | GPR52 (0.68) | GPR52CNR2MRGPRX4 | |
| SCHEMBL3208673 | 0.84 | GPR52 (0.52) | GPR52LIPGNR4A2ALDH1A1KDM4E | |
| SCHEMBL1852770 | 0.81 | GPR52 (0.74) | GPR52LIPGNR4A2ALDH1A1KDM4E | |
| SCHEMBL30370117 | 0.79 | GPR52 (0.54) | GPR52LIPGNR4A2ALDH1A1KDM4E | |
| SCHEMBL29016605 | 0.79 | GPR52 (0.54) | GPR52LIPGNR4A2ALDH1A1KDM4E | |
| SCHEMBL1855792 | 0.79 | GPR52 (0.51) | GPR52NR4A2ALDH1A1KDM4EMEN1 | |
| SCHEMBL1853402 | 0.78 | GPR52 (0.75) | GPR52NR4A2 | |
| SCHEMBL1851314 | 0.77 | ACSL1 (0.47) | GPR52NR4A2ALDH1A1KDM4EMEN1 | |
| SCHEMBL1854736 | 0.76 | GPR52 (0.68) | GPR52LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885LIPG 4574/4885NR4A2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.